SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 141.83 |
| Enterprise Value ($M) | -32.75 |
| Book Value ($M) | 111.22 |
| Book Value / Share | 1.35 |
| Price / Book | 1.28 |
| NCAV ($M) | 65.17 |
| NCAV / Share | 0.79 |
| Price / NCAV | 2.18 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.91 |
| Return on Assets (ROA) | -0.26 |
| Return on Equity (ROE) | -0.83 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.09 |
| Current Ratio | 3.09 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 405.78 |
| Assets | 451.83 |
| Liabilities | 340.61 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Point72 Asset Management, L.P. | 3.70 | -49.48 | |
| 13G/A | Biotechnology Value Fund L P | 0.00 | -100.00 | |
| 13G/A | Rubric Capital Management LP | 0.00 | -100.00 | |
| 13G/A | Adage Capital Management, L.P. | 2.75 | ||
| 13G/A | Vanguard Group Inc | 5.11 | 0.00 | |
| 13G/A | Integrated Core Strategies (us) Llc | 2.50 | -41.14 | |
| 13G/A | Suvretta Capital Management, Llc | 9.50 | 3.83 | |
| 13G/A | Adage Capital Partners Gp, L.l.c. | 7.33 | 25.88 | |
| 13G/A | BlackRock, Inc. | 9.60 | 19.83 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| w, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 184,971 | 729,055 | 25.37 | |
| 212,335 | 848,520 | 25.02 | |
| 135,954 | 536,996 | 25.32 | |
| 252,434 | 868,373 | 29.07 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| SKYE – Skye Bioscience, Inc. | SMMT – Summit Therapeutics Inc. |
| SPRY – ARS Pharmaceuticals, Inc. | SUPN – Supernus Pharmaceuticals, Inc. |
| TARA – Protara Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io